GlassScriptPhysician profile
Brian S Vincent
NPI 1487806485
$1,352.67
in general payments reported to CMS, 2019-2025
25 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $112 · 2023: $83.92 · 2024: $606 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,118.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $288.97 | 2024-2025 | |
| Orthofix Medical, INC. | $142.25 | 2025 | Physio-Stim |
| Lilly USA, LLC | $116.03 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Dynavax Technologies Corporation | $95.64 | 2023-2025 | Heplisav-B |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.20 | 2024-2025 | Xifaxan, Trulance |
| Nestle Healthcare Nutrition INC. | $61.11 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.55 | 2022-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $53.51 | 2021-2025 | Vaxelis, Gardasil 9, Rotateq |
| Amgen INC. | $51.30 | 2024 | Repatha, Otezla |
| Active Medical, LLC | $50.61 | 2025 | |
| Glaxosmithkline, LLC. | $50.53 | 2024-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Ironshore Pharmaceuticals INC. | $49.47 | 2024 | |
| Novo Nordisk INC | $47.44 | 2023-2024 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $30.45 | 2022-2024 | Trintellix |
| Solventum Corporation | $24.43 | 2025 | Prevena |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $22.55 | 2022 | |
| Abbvie INC. | $22.15 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.50 | 2023 | Synjardy, Jardiance, Tradjenta |
| Biohaven Pharmaceutical Holding Company LTD. | $18.63 | 2022 | |
| Axsome Therapeutics, INC. | $16.27 | 2024 | Auvelity |
| Harmony Biosciences LLC | $16.10 | 2024 | |
| Becton, Dickinson and Company | $16.02 | 2025 | Bd Onclarity |
| Abbott Laboratories | $15.65 | 2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $13.24 | 2021 | |
| Organon LLC | $9.07 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Vincent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.